- Home
- SND vs ELDN Comparison
SND vs ELDN Comparison
Compare SND & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SND | ELDN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 235.1M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SND | ELDN |
|---|---|---|
| Price | $5.08 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 321.2K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $163.83 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.76 | $1.35 |
| 52 Week High | $5.84 | $4.60 |
Technical Indicators
Market Signals| Indicator | SND | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 77.08 |
| Support Level | $3.56 | $2.45 |
| Resistance Level | $5.71 | $4.60 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 70.48 | 90.00 |
Price Performance
Historical ComparisonAbout SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.